i would like to thank Jan Geissler for sharing his summary of all the relevant ASH abstracts.
Jan, Giora and Cheryl-Anne are flying to the US this week to attend this important event. they will be working hard taking notes of presentations and updating us on the most exciting data.
take a look at the abstracts by clicking on the ASH 2007 button at the top left side of this page.
please take particular note of the following:
#28 Sustained Molecular Response with Interferon Maintainance Therapy After Imatinib.
#25 IRIS- 6 Year Followup.
#27 Time to CCR Does Not Affect Long Term Outcomes for Patients on Imatinib.
#735 Nilotinib is Highly Effective and Safe in cp CML Patients with Imatinib Resistance/Intolerance.
#1040 Nilotinib is Associated with Minimal Cross-Intolerance in Patients with Imatinib Intolerance.
#1097 Reduced Intensity SCT and DLI After Imatinib Induction
uplifting stuff!
Sandy